Molecular Management of High-Grade Serous Ovarian Carcinoma

Fecha de publicación: 09/11/2022 Fecha Ahead of Print: 09/11/2022

Autores de IIS La Fe

Víctor Lago Leal

Autor
Santiago Domingo Del Pozo

Autor
Carlos Simon Valles

Autor

Participantes ajenos a IIS La Fe

Punzon-Jimenez, Paula
Mas, Aymara

Grupos

Medicina Reproductiva

Investigador Principal

José Morales Roselló

Abstract

High-grade serous ovarian carcinoma (HGSOC) represents the most common form of epithelial ovarian carcinoma. The absence of specific symptoms leads to late-stage diagnosis, making HGSOC one of the gynecological cancers with the worst prognosis. The cellular origin of HGSOC and the role of reproductive hormones, genetic traits (such as alterations in P53 and DNA-repair mechanisms), chromosomal instability, or dysregulation of crucial signaling pathways have been considered when evaluating prognosis and response to therapy in HGSOC patients. However, the detection of HGSOC is still based on traditional methods such as carbohydrate antigen 125 (CA125) detection and ultrasound, and the combined use of these methods has yet to support significant reductions in overall mortality rates. The current paradigm for HGSOC management has moved towards early diagnosis via the non-invasive detection of molecular markers through liquid biopsies. This review presents an integrated view of the relevant cellular and molecular aspects involved in the etiopathogenesis of HGSOC and brings together studies that consider new horizons for the possible early detection of this gynecological cancer.

Datos de la publicación

ISSN/ISSNe:: 1661-6596, 1661-6596
Tipo:: Review
Páginas:: -
DOI:: 10.3390/ijms232213777
Factor de Impacto:: 1,176 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Punzon-Jimenez, Paula:: 1 Carlos Simon Fdn, INCLIVA Hlth Res Inst, Valencia 46010, Spain, España.

Carlos Simon Foundation, INCLIVA Health Research Institute, 46010 Valencia, Spain
Lago, Victor:: 2 La Fe Univ, Dept Gynecol Oncol, Valencia 46026, Spain, España.

3 Polytech Hosp, Valencia 46026, Spain, España.

4 CEU Cardenal Herrera Univ, Dept Obstet & Gynecol, Valencia 46115, Spain, España.

Department of Gynecologic Oncology, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain

Department of Obstetrics and Gynecology, CEU Cardenal Herrera University, 46115 Valencia, Spain
Domingo, Santiago:: 2 La Fe Univ, Dept Gynecol Oncol, Valencia 46026, Spain, España.

3 Polytech Hosp, Valencia 46026, Spain, España.

5 Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia 46010, Spain, España.

Department of Gynecologic Oncology, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain

Department of Pediatrics, Obstetrics and Gynecology, Universidad de Valencia, 46010 Valencia, Spain
Simon, Carlos:: 1 Carlos Simon Fdn, INCLIVA Hlth Res Inst, Valencia 46010, Spain, España.

5 Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia 46010, Spain, España.

6 Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Pediat Obstet & Gynecol, Boston, MA 02215 USA, Estados Unidos America.

7 Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA, Estados Unidos America.

Carlos Simon Foundation, INCLIVA Health Research Institute, 46010 Valencia, Spain

Department of Pediatrics, Obstetrics and Gynecology, Universidad de Valencia, 46010 Valencia, Spain

Department of Pediatrics, Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215, USA

Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX 77030, USA
Mas, Aymara:: 1 Carlos Simon Fdn, INCLIVA Hlth Res Inst, Valencia 46010, Spain, España.

Carlos Simon Foundation, INCLIVA Health Research Institute, 46010 Valencia, Spain